{"title":"Successful Treatment of Necrobiosis Lipoidica with Abrocitinib: A Case Report.","authors":"Yuping Zhang, Yirong Li, Fengjiao Meng, Chen Li","doi":"10.1159/000546134","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Necrobiosis lipoidica (NL) is a rare granulomatous disease with no standardized treatment guidelines.</p><p><strong>Case presentation: </strong>We present a case of a patient who experienced ulcerative NL of the left leg for 5 years, during which traditional treatments proved ineffective. The patient was administered oral abrocitinib at a dosage of 100 mg per day. After 2 weeks of treatment, the patient's skin lesions ceased exuding and began to show improvement. By the 10-week mark, the patient's symptoms had significantly improved, with the ulcer healing and no new lesions appearing. No adverse events were reported during the 4-month follow-up period.</p><p><strong>Conclusion: </strong>Abrocitinib may represent a rapid and safe treatment option for patients with refractory localized NL. Further studies are warranted to confirm these findings and evaluate long-term efficacy.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"17 1","pages":"181-184"},"PeriodicalIF":0.9000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140610/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000546134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Necrobiosis lipoidica (NL) is a rare granulomatous disease with no standardized treatment guidelines.
Case presentation: We present a case of a patient who experienced ulcerative NL of the left leg for 5 years, during which traditional treatments proved ineffective. The patient was administered oral abrocitinib at a dosage of 100 mg per day. After 2 weeks of treatment, the patient's skin lesions ceased exuding and began to show improvement. By the 10-week mark, the patient's symptoms had significantly improved, with the ulcer healing and no new lesions appearing. No adverse events were reported during the 4-month follow-up period.
Conclusion: Abrocitinib may represent a rapid and safe treatment option for patients with refractory localized NL. Further studies are warranted to confirm these findings and evaluate long-term efficacy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
